Diseases

10 Dec
Categories Diseases, Genetics, Metabolic Medicine, speciality

Minagene’s Metabolic Genetics










Overview


Minagene's Metabolic Genetics is an advanced genetic testing service that focuses on unraveling the genetic basis of metabolic disorders. By analyzing specific genetic variants associated with various metabolic conditions, this comprehensive test provides valuable insights into the molecular underpinnings of these disorders, enabling accurate diagnosis, personalized treatment strategies, and improved patient care in the field of metabolic medicine.


Methodology



The Metabolic Genetics test


The Metabolic Genetics test utilizes state-of-the-art genetic analysis techniques, including next-generation sequencing and targeted genotyping, to examine genes known to be associated with metabolic disorders. By analyzing an individual’s genetic profile, this test provides clinicians with crucial information regarding disease-causing variants, potential disease progression, and response to specific treatments.


Key Highlights of the Test:


Key Highlights of the Test:






    • Precise Diagnosis: The Metabolic Genetics test enables precise diagnosis by identifying genetic variants associated with a broad range of metabolic disorders. By uncovering the underlying genetic factors contributing to a patient’s metabolic condition, clinicians can achieve a more accurate diagnosis, leading to tailored treatment plans and improved patient management.




    • Personalized Treatment Strategies: By analyzing an individual’s genetic profile, the test helps in developing personalized treatment strategies for metabolic disorders. It provides insights into potential drug targets, response to specific medications, and the likelihood of disease progression, allowing clinicians to optimize treatment plans and achieve better therapeutic outcomes.




    • Identification of Disease-Causing Variants: The test identifies disease-causing genetic variants associated with various metabolic disorders, including inborn errors of metabolism, lipid disorders, glucose disorders, and mitochondrial disorders, among others. This information helps clinicians understand the genetic basis of the disease and provides valuable guidance for patient management and counseling.




    • Proactive Disease Management: Genetic information obtained from the test allows for proactive disease management by identifying individuals at higher risk of developing certain metabolic disorders. This enables early intervention, regular monitoring, and the implementation of preventive measures to mitigate the progression or severity of the condition.




    • Research Advancements: The Metabolic Genetics test contributes to ongoing research efforts in the field of metabolic medicine. By analyzing a large cohort of patients with diverse metabolic conditions, the test generates valuable data that can be used to further understand the genetic basis of these disorders, develop novel therapies, and advance the field of precision medicine in metabolic disorders.






When to Consider This Test:






    • Diagnostic Dilemmas: The Metabolic Genetics test is particularly valuable in cases where traditional diagnostic approaches have been inconclusive or when there is a suspicion of a genetic component underlying the metabolic condition. It can provide crucial insights into the genetic basis of the disease, leading to a more accurate diagnosis and appropriate management strategies.




    • Inborn Errors of Metabolism: The test is beneficial when evaluating individuals with suspected inborn errors of metabolism, such as phenylketonuria, maple syrup urine disease, or urea cycle disorders. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment decisions for affected individuals.




    • Lipid Disorders: The test assists in the diagnosis and management of lipid disorders, including familial hypercholesterolemia, familial combined hyperlipidemia, and dyslipidemias. It identifies genetic variants associated with these conditions, provides prognostic information, and helps guide treatment decisions for affected individuals.




    • Glucose Disorders: The test provides insights into the genetic basis of glucose disorders, such as diabetes mellitus, maturity-onset diabetes of the young (MODY), and congenital hyperinsulinism. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment strategies for affected individuals.




    • Mitochondrial Disorders: The Metabolic Genetics test can provide insights into the genetic basis of mitochondrial disorders, including mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), Leigh syndrome, and mitochondrial myopathies. It helps identify genetic variants associated with these conditions, predicts disease progression, and assists in selecting appropriate management strategies for affected individuals.




    • Research and Clinical Trials: The test contributes to ongoing research efforts and clinical trials in the field of metabolic medicine. By participating in genetic studies, patients can help advance knowledge about metabolic disorders, potentially leading to the development of new treatments and therapeutic approaches.





Read More
10 Dec
Categories Cardiology, Diseases, Genetics, speciality

Minagene’s Cardio Genetics










Overview


Minagene's Cardio Genetics is an advanced genetic testing service that focuses on uncovering the genetic basis of cardiovascular disorders. By analyzing specific genetic variants associated with various heart and vascular conditions, this comprehensive test provides valuable insights into the molecular underpinnings of these disorders, enabling accurate diagnosis, personalized treatment strategies, and improved patient care in the field of cardiology.


Methodology



The Cardio Genetics test


The Cardio Genetics test utilizes cutting-edge genetic analysis techniques, including next-generation sequencing and targeted genotyping, to examine genes known to be associated with cardiovascular disorders. By analyzing an individual’s genetic profile, this test provides clinicians with crucial information regarding disease-causing variants, potential disease progression, and response to specific treatments.


Key Highlights of the Test:


Key Highlights of the Test:




  • Precise Diagnosis: The Cardio Genetics test enables precise diagnosis by identifying genetic variants associated with a wide range of cardiovascular disorders. By uncovering the underlying genetic factors contributing to a patient’s heart or vascular condition, clinicians can achieve a more accurate diagnosis, leading to tailored treatment plans and improved patient management.




  • Personalized Treatment Strategies: By analyzing an individual’s genetic profile, the test helps in developing personalized treatment strategies for cardiovascular disorders. It provides insights into potential drug targets, response to specific medications, and the likelihood of disease progression, allowing clinicians to optimize treatment plans and achieve better therapeutic outcomes.




  • Identification of Disease-Causing Variants: The test identifies disease-causing genetic variants associated with various cardiovascular disorders, including inherited cardiac conditions, arrhythmias, cardiomyopathies, and aortic diseases, among others. This information helps clinicians understand the genetic basis of the disease and provides valuable guidance for patient management and counseling.




  • Proactive Disease Management: Genetic information obtained from the test allows for proactive disease management by identifying individuals at higher risk of developing certain cardiovascular disorders. This enables early intervention, regular monitoring, and the implementation of preventive measures to mitigate the progression or severity of the condition.




  • Research Advancements: The Cardio Genetics test contributes to ongoing research efforts in the field of cardiology. By analyzing a large cohort of patients with diverse cardiovascular conditions, the test generates valuable data that can be used to further understand the genetic basis of these disorders, develop novel therapies, and advance the field of precision medicine in cardiology.




When to Consider This Test:






    • Diagnostic Dilemmas: The Cardio Genetics test is particularly valuable in cases where traditional diagnostic approaches have been inconclusive or when there is a suspicion of a genetic component underlying the cardiovascular condition. It can provide crucial insights into the genetic basis of the disease, leading to a more accurate diagnosis and appropriate management strategies.




    • Inherited Cardiac Conditions: The test is beneficial when evaluating individuals with a family history of inherited cardiac conditions, such as hypertrophic cardiomyopathy, long QT syndrome, or familial hypercholesterolemia. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment decisions for affected individuals and their family members.




    • Arrhythmias and Conduction Disorders: The test assists in the diagnosis and management of arrhythmias and conduction disorders, including atrial fibrillation, ventricular tachycardia, and Brugada syndrome. It identifies genetic variants associated with these conditions, provides prognostic information, and helps guide treatment decisions for affected individuals.




    • Cardiomyopathies: The test provides insights into the genetic basis of cardiomyopathies, such as dilated cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment strategies for affected individuals.




    • Aortic Diseases: The Cardio Genetics test can provide insights into the genetic basis of aortic diseases, including thoracic aortic aneurysms and aortic dissections. It helps identify genetic variants associated with these conditions, predicts disease progression, and assists in selecting appropriate management strategies for affected individuals.




    • Research and Clinical Trials: The test contributes to ongoing research efforts and clinical trials in the field of cardiology. By participating in genetic studies, patients can help advance knowledge about cardiovascular disorders, potentially leading to the development of new treatments and therapeutic approaches.





Read More
10 Dec
Categories Diseases, Genetics, Neurology, speciality

Minagene’s Neuro Genetics










Overview


Minagene's Neuro Genetics is an advanced genetic testing service that focuses on unraveling the genetic basis of neurological disorders. By analyzing specific genetic variants associated with various neurological conditions, this comprehensive test provides valuable insights into the molecular underpinnings of these disorders, enabling accurate diagnosis, personalized treatment strategies, and improved patient care in the field of neurology.


Methodology



The Neuro Genetics test


The Neuro Genetics test utilizes state-of-the-art genetic analysis techniques, including next-generation sequencing and targeted genotyping, to examine genes known to be associated with neurological disorders. By analyzing an individual’s genetic profile, this test provides clinicians with vital information regarding disease-causing variants, potential disease progression, and response to specific treatments.


Key Highlights of the Test:


Key Highlights of the Test:






    • Precise Diagnosis: The Neuro Genetics test enables precise diagnosis by identifying genetic variants associated with a broad range of neurological disorders. By uncovering the underlying genetic factors contributing to a patient’s neurological condition, clinicians can achieve a more accurate diagnosis, leading to tailored treatment plans and improved patient management.




    • Personalized Treatment Strategies: By analyzing an individual’s genetic profile, the test helps in developing personalized treatment strategies for neurological disorders. It provides insights into potential drug targets, response to specific medications, and the likelihood of disease progression, allowing clinicians to optimize treatment plans and achieve better therapeutic outcomes.




    • Identification of Disease-Causing Variants: The test identifies disease-causing genetic variants associated with various neurological disorders, including neurodevelopmental disorders, neurodegenerative diseases, neuromuscular disorders, and epilepsy, among others. This information helps clinicians understand the genetic basis of the disease and provides valuable guidance for patient management and counseling.




    • Proactive Disease Management: Genetic information obtained from the test allows for proactive disease management by identifying individuals at higher risk of developing certain neurological disorders. This enables early intervention, regular monitoring, and the implementation of preventive measures to mitigate the progression or severity of the condition.




    • Research Advancements: The Neuro Genetics test contributes to ongoing research efforts in the field of neurology. By analyzing a large cohort of patients with diverse neurological conditions, the test generates valuable data that can be used to further understand the genetic basis of these disorders, develop novel therapies, and advance the field of precision medicine in neurology.






When to Consider This Test:






    • Diagnostic Dilemmas: The Neuro Genetics test is particularly valuable in cases where traditional diagnostic approaches have been inconclusive or when there is a suspicion of a genetic component underlying the neurological condition. It can provide crucial insights into the genetic basis of the disease, leading to a more accurate diagnosis and appropriate management strategies.




    • Neurodevelopmental Disorders: The test is beneficial when evaluating individuals with neurodevelopmental disorders, such as autism spectrum disorders, intellectual disabilities, and developmental delays. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment decisions for affected individuals and their families.




    • Neurodegenerative Diseases: The test assists in the diagnosis and management of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. It identifies disease-associated genetic variants, provides prognostic information, and helps guide treatment decisions for affected individuals.




    • Neuromuscular Disorders: The test is valuable in evaluating individuals with neuromuscular disorders, such as muscular dystrophies, myopathies, and motor neuron diseases. It aids in identifying disease-causing genetic variants, understanding disease progression, and guiding treatment strategies for affected individuals.




    • Epilepsy and Seizure Disorders: The Neuro Genetics test can provide insights into the genetic basis of epilepsy and seizure disorders. It helps identify genetic variants associated with these conditions, predicts treatment response, and assists in selecting appropriate antiepileptic medications for optimal seizure control.




    • Research and Clinical Trials: The test contributes to ongoing research efforts and clinical trials in the field of neurology. By participating in genetic studies, patients can help advance knowledge about neurological disorders, potentially leading to the development of new treatments and therapeutic approaches.





Read More
10 Dec
Categories Diseases, Genetics, Nephrology, speciality

Minagene’s Nephro Genetics










Overview


Minagene's Nephro Genetics is a specialized genetic testing service that focuses on the genetic factors underlying various kidney disorders. By analyzing specific genetic variants associated with renal conditions, this comprehensive test provides valuable insights into the molecular basis of kidney diseases, enabling accurate diagnosis, personalized treatment strategies, and improved patient care in the field of nephrology.


Methodology



The Nephro Genetics test utilizes


The Nephro Genetics test utilizes cutting-edge genetic analysis techniques, including next-generation sequencing and targeted genotyping, to examine genes known to be associated with kidney disorders. By analyzing an individual’s genetic profile, this test provides clinicians with valuable information regarding disease-causing variants, potential disease progression, and response to specific treatments.


Key Highlights of the Test:


Key Highlights of the Test:






    • Precise Diagnosis: The Nephro Genetics test enables precise diagnosis by identifying genetic variants associated with various kidney disorders. By uncovering the underlying genetic factors contributing to a patient’s renal condition, clinicians can achieve a more accurate diagnosis, leading to tailored treatment plans and improved patient management.




    • Personalized Treatment Strategies: By analyzing an individual’s genetic profile, the test helps in developing personalized treatment strategies for kidney disorders. It provides insights into potential drug targets, response to specific medications, and the likelihood of disease progression, allowing clinicians to optimize treatment plans and achieve better therapeutic outcomes.




    • Identification of Disease-Causing Variants: The test identifies disease-causing genetic variants associated with a wide range of kidney disorders, including inherited kidney diseases, glomerular diseases, tubulopathies, and cystic kidney diseases, among others. This information helps clinicians understand the genetic basis of the disease and provides valuable guidance for patient management and counseling.




    • Proactive Disease Management: Genetic information obtained from the test allows for proactive disease management by identifying individuals at higher risk of developing certain kidney disorders. This enables early intervention, regular monitoring, and the implementation of preventive measures to mitigate the progression or severity of the condition.




    • Research Advancements: The Nephro Genetics test contributes to ongoing research efforts in the field of nephrology. By analyzing a large cohort of patients with diverse renal conditions, the test generates valuable data that can be used to further understand the genetic basis of these disorders, develop novel therapies, and advance the field of precision medicine in nephrology.






When to Consider This Test:






    • Diagnostic Dilemmas: The Nephro Genetics test is particularly valuable in cases where traditional diagnostic approaches have been inconclusive or when there is a suspicion of a genetic component underlying the renal condition. It can provide crucial insights into the genetic basis of the disease, leading to a more accurate diagnosis and appropriate management strategies.




    • Inherited Kidney Disorders: The test is beneficial when evaluating individuals with a family history of inherited kidney diseases. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment decisions for affected individuals and their family members.




    • Treatment Optimization: The test assists in optimizing treatment plans for kidney disorders by providing information on an individual’s genetic profile and drug response. This enables clinicians to select the most appropriate medications, adjust dosages, and personalize treatment strategies to maximize therapeutic benefits.




    • Risk Assessment and Counseling: The test aids in assessing an individual’s risk of developing certain kidney disorders, particularly in cases where there is a known genetic predisposition. This information allows for proactive management, genetic counseling, and the implementation of preventive measures to reduce disease risk.




    • Research and Clinical Trials: The Nephro Genetics test contributes to ongoing research efforts and clinical trials in the field of nephrology. By participating in genetic studies, patients can help advance knowledge about kidney disorders, potentially leading to the development of new treatments and therapeutic approaches





Read More
05 Dec
Categories Cardiology, Diseases, Immunology, Neurology, Oncology, Pediatrics, speciality

Minagene’s Clinical Exome V4










Overview


Minagene's Clinical Exome V4 is an advanced genetic testing service that utilizes state-of-the-art sequencing technologies to analyze the protein-coding regions of the genome, known as the exome. By examining thousands of genes associated with various genetic disorders, this comprehensive test provides clinicians with valuable insights into the molecular basis of complex and rare diseases, enabling accurate diagnosis, personalized treatment strategies, and improved patient care.


Methodology



The Clinical Exome


The Clinical Exome V4 test employs next-generation sequencing techniques to capture and sequence the exonic regions of an individual’s genome. This high-throughput approach allows for the analysis of thousands of genes simultaneously, providing a broad and in-depth assessment of the genetic variants that may contribute to a patient’s condition.


Key Highlights of the Test:


Key Highlights of the Test:




  • Comprehensive Genetic Analysis: The Clinical Exome V4 test offers a comprehensive analysis of the exome, covering a vast number of disease-associated genes. By examining a wide range of genetic variants, including single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number variations (CNVs), the test provides a comprehensive view of the patient’s genetic landscape, aiding in the identification of disease-causing variants.




  • Accurate Diagnosis: The test enables accurate diagnosis by identifying pathogenic or likely pathogenic variants associated with genetic disorders. By comparing the patient’s genetic profile with a vast database of known disease-associated variants, the test helps clinicians pinpoint the underlying cause of the patient’s condition, leading to more precise diagnoses and appropriate treatment plans.




  • Personalized Treatment Strategies: The Clinical Exome V4 test assists in developing personalized treatment strategies by identifying genetic variants that may impact drug response or guide targeted therapies. By understanding an individual’s unique genetic makeup, clinicians can tailor treatment plans, select appropriate medications, and optimize therapeutic outcomes.




  • Identification of Rare and Novel Variants: The test has a particular focus on detecting rare and novel variants that may not be captured by other genetic testing methods. By exploring the exome comprehensively, it enhances the chances of identifying unique genetic variants that may be responsible for a patient’s condition, even in cases where a diagnosis was previously elusive.




  • Enhanced Variant Interpretation: Minagene’s Clinical Exome V4 benefits from advanced variant interpretation algorithms and a curated variant knowledgebase. This enables clinicians to access up-to-date information on variant pathogenicity, supporting accurate variant classification and reducing the risk of misinterpretation.




When to Consider This Test:




  • Complex and Undiagnosed Cases: The Clinical Exome V4 test is particularly valuable in complex and undiagnosed cases where the underlying cause of a patient’s condition is unclear. By conducting a comprehensive analysis of the exome, it increases the chances of identifying disease-causing variants and providing a definitive diagnosis.




  • Rare Genetic Disorders: The test is beneficial in cases suspected to have rare genetic disorders. It enables the detection of rare and novel variants associated with these conditions, aiding in accurate diagnosis, appropriate management, and genetic counseling for patients and their families.




  • Therapeutic Decision-Making: The test assists in therapeutic decision-making by identifying genetic variants that may impact drug response or guide targeted therapies. This information helps clinicians select the most suitable medications, optimize treatment plans, and improve patient outcomes.




  • Family Screening and Counseling: The Clinical Exome V4 test supports family screening and counseling for genetic disorders. By identifying disease-causing variants, it allows for the identification of at-risk family members and facilitates informed decision-making regarding family planning and genetic counseling.




  • Research and Clinical Trials: The test contributes to research efforts and clinical trials focused on genetic disorders. By participating in genetic studies, patients can help advance knowledge about rare diseases, potentially leading to the development of new treatments and therapeutic approaches.



Read More
05 Dec
Categories Diseases, Immunology, Neurology, Oncology, Ophthalmology, speciality

Minagene’s Genetics of Ophthalmic Disorders: Advancing Precision Medicine in Ophthalmology










Overview


Minagene's Genetics of Ophthalmic Disorders is a comprehensive genetic testing service that focuses on the genetic factors underlying various ophthalmic conditions. By analyzing specific genetic variants associated with ocular disorders, this test provides valuable insights into the molecular basis of these conditions, enabling precise diagnosis, personalized treatment strategies, and improved patient outcomes in the field of ophthalmology.


Methodology



The Genetics of Ophthalmic


The Genetics of Ophthalmic Disorders test utilizes state-of-the-art genetic analysis techniques, including next-generation sequencing and targeted genotyping, to examine genes known to be associated with different ophthalmic conditions. By analyzing an individual’s genetic profile, this test provides clinicians with valuable information regarding disease-causing variants, potential disease progression, and response to specific treatments.


Key Highlights of the Test:


Key Highlights of the Test:




  • Precise Diagnosis: The Genetics of Ophthalmic Disorders test enables precise diagnosis by identifying genetic variants associated with various ocular conditions. By uncovering the underlying genetic factors contributing to a patient’s disease, clinicians can achieve a more accurate diagnosis, leading to tailored treatment plans and improved patient management.




  • Personalized Treatment Strategies: By analyzing an individual’s genetic profile, the test helps in developing personalized treatment strategies for ophthalmic disorders. It provides insights into potential drug targets, response to specific medications, and the likelihood of disease progression, allowing clinicians to optimize treatment plans and achieve better therapeutic outcomes.




  • Identification of Disease-Causing Variants: The test identifies disease-causing genetic variants associated with a wide range of ophthalmic disorders, including inherited retinal diseases, glaucoma, cataracts, and corneal dystrophies, among others. This information helps clinicians understand the genetic basis of the disease and provides valuable guidance for patient management and counseling.




  • Proactive Disease Management: Genetic information obtained from the test allows for proactive disease management by identifying individuals at higher risk of developing certain ophthalmic disorders. This enables early intervention, regular monitoring, and the implementation of preventive measures to mitigate the progression or severity of the condition.




  • Research Advancements: The Genetics of Ophthalmic Disorders test contributes to ongoing research efforts in the field of ophthalmology. By analyzing a large cohort of patients with diverse ocular conditions, the test generates valuable data that can be used to further understand the genetic basis of these disorders, develop novel therapies, and advance the field of precision medicine in ophthalmology.




When to Consider This Test:




  • Diagnostic Dilemmas: The Genetics of Ophthalmic Disorders test is particularly valuable in cases where traditional diagnostic approaches have been inconclusive or when there is a suspicion of a genetic component underlying the ocular condition. It can provide crucial insights into the genetic basis of the disease, leading to a more accurate diagnosis and appropriate management strategies.




  • Inherited Ophthalmic Conditions: The test is beneficial when evaluating individuals with a family history of inherited ophthalmic disorders. It helps identify disease-causing genetic variants, predict disease progression, and guide treatment decisions for affected individuals and their family members.




  • Treatment Optimization: The test assists in optimizing treatment plans for ophthalmic disorders by providing information on an individual’s genetic profile and drug response. This enables clinicians to select the most appropriate medications, adjust dosages, and personalize treatment strategies to maximize therapeutic benefits.




  • Risk Assessment and Counseling: The test aids in assessing an individual’s risk of developing certain ophthalmic disorders, particularly in cases where there is a known genetic predisposition. This information allows for proactive management, genetic counseling, and the implementation of preventive measures to reduce disease risk.




  • Research and Clinical Trials: The Genetics of Ophthalmic Disorders test contributes to ongoing research efforts and clinical trials in the field of ophthalmology. By participating in genetic studies, patients can help advance knowledge about ocular conditions, potentially leading to the development of new treatments and therapeutic approaches.



Read More
05 Dec
Categories Cardiology, Diseases, Gynecology and obstetrics, Immunology, Oncology, speciality

Minagene’s Trio Exome Test





Overview


Trio Exome Analysis is a powerful approach in the field of genetic diagnostics, specifically tailored to identify causal mutations for inherited diseases. This method utilizes next-generation sequencing (NGS) technology to simultaneously sequence the coding regions of all genes within a family pedigree, providing valuable insights into the genetic basis of the disease.


By analyzing the trio, consisting of the affected individual and both parents, Trio Exome Analysis can detect variants inherited from the parents that may cause recessive or dominant diseases. Additionally, it can identify de novo variants that arise in the offspring but are not present in either parent.


Methodology


Genomic DNA

Genomic DNA extracted from blood samples is subjected to NGS using an Illumina platform, capturing and sequencing the coding regions of all genes. The resulting sequence data is aligned and analyzed for sequence variants.


Key Highlights of the Test:


Key Highlights of the Test:




    • Diagnostic Odyssey Resolution: Trio analysis becomes instrumental in cases where alternative diagnostic techniques fail to confirm a diagnosis, providing a pathway to end the diagnostic odyssey.




    • Enhanced Patient Management: Trio analysis aids in better patient management and can facilitate prenatal diagnosis where applicable, empowering physicians to provide more targeted care.




    • Overcoming Clinical Heterogeneity: Trio Exome Analysis is particularly valuable in situations where definitive clinical diagnosis is challenging due to clinical heterogeneity, especially for rare congenital disorders where traditional methods fall short in identifying the causal variant.




    Trio Exome Analysis, utilizing whole exome or clinical exome sequencing, enables the simultaneous analysis of thousands of genes. This approach allows for the identification of various genetic alterations, including insertions/deletions (indels), single nucleotide variants (SNVs), and copy number variations (CNVs). Moreover, this familial analysis-based approach assists in excluding variants that do not conform to Mendelian transmission, reducing false positive calls and narrowing down potential candidate variants.




  • Compared to analyzing only the proband, the overall diagnostic yield of Trio Exome Analysis utilizing exome sequencing has shown a 5-10% increase, emphasizing its significant contribution to genetic diagnostics.




Situations Where Trio Exome Test Can Be Used:

The Trio Exome Test is recommended when an individual’s medical examination, laboratory findings, and family history suggest an underlying genetic etiology. Here are some scenarios where the test can be valuable:




  • Undiagnosed Genetic Diseases: When extensive evaluation and multiple genetic tests fail to identify the cause of a genetic disease, Trio Exome Analysis can provide valuable insights for diagnosis.




  • Medical Intervention and Treatment: Trio analysis can facilitate medical intervention, treatment planning, and personalized care based on the identified genetic variants.




  • Reproductive Planning and Recurrence Risk Assessment: Trio Exome Analysis aids in guiding reproductive planning and assessing the risk of recurrence for genetically heterogeneous diseases, where multiple genes can cause the same disease or condition.




  • Prognosis and Family History: Trio analysis also plays a role in prognosis, particularly when considering family history and its implications for disease management and treatment.




  • By leveraging Trio Exome Analysis, physicians can unlock a deeper understanding of inherited diseases, leading to improved patient care, earlier interventions, and more informed reproductive counseling.





Minagene's Trio Exome Test


Overview
Trio Exome Analysis is a powerful approach in the field of genetic diagnostics, specifically tailored to identify causal mutations for inherited diseases. This method utilizes next-generation sequencing (NGS) technology to simultaneously sequence the coding regions of all genes within a family pedigree, providing valuable insights into the genetic basis of the disease.

By analyzing the trio, consisting of the affected individual and both parents, Trio Exome Analysis can detect variants inherited from the parents that may cause recessive or dominant diseases. Additionally, it can identify de novo variants that arise in the offspring but are not present in either parent.

Methodology
Genomic DNA extracted from blood samples is subjected to NGS using an Illumina platform, capturing and sequencing the coding regions of all genes. The resulting sequence data is aligned and analyzed for sequence variants.

Key Highlights of Minagene’s NIPT


  • Diagnostic Odyssey Resolution: Trio analysis becomes instrumental in cases where alternative diagnostic techniques fail to confirm a diagnosis, providing a pathway to end the diagnostic odyssey.



  • Enhanced Patient Management: Trio analysis aids in better patient management and can facilitate prenatal diagnosis where applicable, empowering physicians to provide more targeted care.



  • Overcoming Clinical Heterogeneity: Trio Exome Analysis is particularly valuable in situations where definitive clinical diagnosis is challenging due to clinical heterogeneity, especially for rare congenital disorders where traditional methods fall short in identifying the causal variant.



  • Compared to analyzing only the proband, the overall diagnostic yield of Trio Exome Analysis utilizing exome sequencing has shown a 5-10% increase, emphasizing its significant contribution to genetic diagnostics.



  • The Trio Exome Test is recommended when an individual’s medical examination, laboratory findings, and family history suggest an underlying genetic etiology. Here are some scenarios where the test can be valuable:



  • Undiagnosed Genetic Diseases: When extensive evaluation and multiple genetic tests fail to identify the cause of a genetic disease, Trio Exome Analysis can provide valuable insights for diagnosis.



  • Medical Intervention and Treatment: Trio analysis can facilitate medical intervention, treatment planning, and personalized care based on the identified genetic variants.



  • Reproductive Planning and Recurrence Risk Assessment: Trio Exome Analysis aids in guiding reproductive planning and assessing the risk of recurrence for genetically heterogeneous diseases, where multiple genes can cause the same disease or condition.



  • Prognosis and Family History: Trio analysis also plays a role in prognosis, particularly when considering family history and its implications for disease management and treatment.



  • By leveraging Trio Exome Analysis, physicians can unlock a deeper understanding of inherited diseases, leading to improved patient care, earlier interventions, and more informed reproductive counseling.



Diseases


  • Prader-Willi Syndrome



  • Angelman Syndrome



  • Digeorge Syndrome



  • Cystic Fibrosis



  • Spinal Muscular Atrophy



  • Fragile X Syndrome



  • Beta Thalassemia



  • Sickle Cell Disease/Trait



  • Congenital Adrenal Hyperplasia



  • Alpha Thalassemia



  • Intellectual disability



  • Congenital glaucoma



  • Bardet–Biedl syndrome



  • Meckel– Gruber syndrome



  • organic acidaemia



  • lysosomal storage disorders



  • retinal dystrophies



  • Hearing loss and primary microcephaly



  • Thrombocytopenia



  • Spherocytosis



  • Hemolytic anemia



  • G6PD deficient



  • C6 deficiency



  • Aminoacylase 1 deficiency



  • Sitosterolemia 2



  • Chronic granulomatous disease


Read More
05 Dec
Categories Cardiology, Diseases, Immunology, Neurology, Oncology, Pediatrics, speciality

ExomeMax










Overview


Minagene's ExomeMax is a comprehensive genetic evaluation tool designed to enhance diagnostic outcomes by providing improved coverage of disease-associated genes. With an inclusive design and expert augmentation, ExomeMax offers a thorough assessment of inherited disease genes, taking into account the constantly evolving genotype-phenotype associations in the field of genetics.


Key Highlights of Minagene's ExomeMax:



Key Highlights of Minagene's ExomeMax:




  • Enhanced Gene Coverage: ExomeMax includes coverage of alternate gene transcripts (MANE, GENCODE, REFSEQ), ensuring a comprehensive evaluation of disease-associated genes.




  • Non-Coding Pathogenic Variant Coverage: ExomeMax incorporates coverage of non-coding pathogenic variants sourced from HGMD/ClinVar, enabling a more thorough assessment of genetic variations.




  • Complete Mitochondrial Genome Coverage: ExomeMax provides 100% coverage of the mitochondrial genome, allowing for a comprehensive analysis of mitochondrial genetic disorders.




  • ML-Powered Variant Analysis: Variant analysis is powered by machine learning (ML) algorithms, ensuring robust and accurate interpretation of genetic variants. The results are reviewed by certified Clinical Geneticists, adding an additional layer of expertise.




  • Extensive Validation and Proficiency Testing: ExomeMax undergoes extensive validation and proficiency testing, including CAP proficiency testing, to ensure consistency, validity, and accuracy of the results.




  • Specialized Probes for Superior Detection: ExomeMax utilizes specialized probes that enhance the detection of single nucleotide variants (SNVs) and copy number variants (CNVs), improving the sensitivity and specificity of the test.




  • Panel Size and Coverage: ExomeMax covers a panel size of 47 Mb, encompassing over 20,000 genes and more than 210,000 exons.




When to Consider an ExomeMax Test:




  • Clinical Findings or Family History: ExomeMax should be considered when clinical findings or family history suggest an underlying genetic cause for a patient’s condition.




  • Genetically Heterogeneous Diseases: ExomeMax is valuable for screening genetically heterogeneous diseases, where multiple genes can contribute to the same disease or condition.




  • Undiagnosed Genetic Diseases: In cases of undiagnosed genetic diseases, where patients have undergone a diagnostic odyssey without a clear diagnosis, ExomeMax can provide valuable insights.




  • Medical Intervention and Treatment: ExomeMax can facilitate medical intervention and treatment planning based on the identified genetic variants.




  • Confirmation of Suspected Genetic Diagnosis: When there is a suspected genetic diagnosis, ExomeMax can confirm the presence of the suspected genetic variant.




  • Reproductive Planning and Recurrence Risk Assessment: ExomeMax aids in guiding reproductive planning by assessing the risk of recurrence for inherited conditions and providing valuable insights for family planning.




  • Prognosis and Family History: ExomeMax can contribute to determining prognosis based on family history, providing valuable information for disease management and treatment decisions.




Validation




  • ExomeMax undergoes requisite quality controls throughout the workflow, from laboratory sample processing to interpretation, ensuring consistency, validity, and accuracy of the results. The analytical sensitivity of ExomeMax is supported by NIST reference standard NA12878, with a high sensitivity for SNPs (99%) and Indels (96.2%). Copy number variant (CNV) pipeline is evaluated using orthogonally validated methods. Minagene’s proprietary ML-enabled analysis tool is utilized, and the results are reviewed by certified clinical geneticists.




  • Minagene’s ExomeMax provides physicians with a comprehensive and accurate genetic evaluation tool, enabling precise diagnoses, improved patient management, and enhanced reproductive planning.



Read More
05 Dec
Categories Cardiology, Diseases, Immunology, Neurology, Oncology, Pediatrics, speciality

Whole Exome Sequencing










Overview


Whole Exome Sequencing (WES) is a genomic test that examines the complete coding region of the genome, including all coding regions and splice junctions. Unlike targeted gene panels, WES analyzes variations in the protein-coding region of any gene, offering a broader scope for identifying disease-causing mutations. Since most known disease-causing mutations occur in exons, WES is often more effective than whole genome sequencing.


Methodology



Next Generation Sequencing (NGS)


Genomic DNA extracted from blood is used to simultaneously capture and sequence the coding regions of all genes on an Illumina platform. The resulting sequence data is then aligned and analyzed to identify sequence variants.


Key Highlights of the Test:


Key Highlights of the Test:


-Patients with a combination of symptoms that do not provide a precise diagnosis or phenotype of a suspected genetic disease.


-Cases where a delayed differential diagnosis could have a significant impact on the patient’s quality of life.


-Situations where a stepwise diagnostic approach would be costly and time-consuming.


-When physicians are unable to provide a plausible diagnosis based on the presented symptoms.


-When no other available techniques can confirm the diagnosis and put an end to the diagnostic odyssey.


Whole Exome Sequencing offers a comprehensive analysis of the coding regions of the genome, providing valuable insights into genetic diseases and enabling physicians to make more accurate diagnoses for their patients.

Read More
05 Dec
Categories Diseases, Hematology, Oncology, speciality

Minagene’s FLT3 Test










Overview


Minagene's FLT3 Test is a specialized genetic test designed to provide comprehensive analysis of FLT3 mutations in patients with acute myeloid leukemia (AML). This advanced test utilizes state-of-the-art molecular techniques to detect and characterize FLT3 mutations, enabling accurate diagnosis, prognostic assessment, and personalized treatment strategies for individuals with AML.


Methodology



The FLT3 Test employs


The FLT3 Test employs cutting-edge molecular techniques, including polymerase chain reaction (PCR) and DNA sequencing, to detect and analyze FLT3 mutations. It specifically targets the FLT3 gene, which plays a critical role in the regulation of cell growth and proliferation in hematopoietic cells. By analyzing FLT3 mutations, the test provides valuable genetic information that aids in the diagnosis, risk stratification, and treatment selection for AML patients.


Key Highlights of the Test:


Key Highlights of the Test:


-Comprehensive FLT3 Mutation Analysis: Minagene’s FLT3 Test offers a comprehensive analysis of FLT3 mutations in AML patients. It detects both internal tandem duplications (ITDs) and point mutations in the FLT3 gene, including the common FLT3-ITD and FLT3-TKD mutations. This comprehensive approach ensures accurate detection and characterization of FLT3 mutations, which are crucial for clinical decision-making.


-Accurate Diagnosis and Subtyping: The FLT3 Test helps in accurate diagnosis and subtyping of AML by identifying FLT3 mutations. FLT3 mutations are commonly observed in AML and have prognostic implications. The test aids in distinguishing between different AML subtypes and provides critical information for risk stratification and treatment planning.


-Prognostic Assessment: FLT3 mutations have significant prognostic implications in AML. The FLT3 Test provides valuable prognostic information by identifying the presence and type of FLT3 mutations. It helps in risk stratification and treatment decision-making, as patients with FLT3 mutations often have poorer outcomes and may require more aggressive therapeutic approaches.


-Personalized Treatment Selection: The FLT3 Test’s genetic insights assist in personalized treatment selection for AML patients. Identification of FLT3 mutations helps in determining the eligibility for targeted therapies, such as FLT3 inhibitors, which specifically target the mutated FLT3 protein. This information guides clinicians in selecting appropriate treatment strategies to improve patient outcomes.


-Monitoring Treatment Response: The FLT3 Test can be used to monitor treatment response in AML patients with FLT3 mutations. By periodically assessing the presence and levels of FLT3 mutations, the test helps evaluate the effectiveness of targeted therapies and make necessary treatment adjustments based on the molecular response.


When to Consider This Test:


-Diagnostic Evaluation: The FLT3 Test is recommended for patients with suspected or newly diagnosed AML. It aids in accurate diagnosis and subclassification of AML by detecting FLT3 mutations, providing valuable information for risk assessment and treatment planning.


-Prognostic Assessment: The test is valuable for prognostic assessment in AML patients. FLT3 mutations are associated with poorer outcomes, and their detection helps in risk stratification and treatment decision-making.


-Treatment Selection: The FLT3 Test assists in personalized treatment selection for AML patients. Identification of FLT3 mutations determines the eligibility for targeted therapies, such as FLT3 inhibitors, which can be used as part of the treatment regimen.


-Treatment Response Monitoring: The test can be utilized for monitoring treatment response in AML patients with FLT3 mutations. It helps evaluate the effectiveness of targeted therapies and guides treatment adjustments based on the molecular response.


-Research and Clinical Trials: The FLT3 Test can be used in research studies and clinical trials focusing on AML. The test’s comprehensive analysis of FLT3 mutations contributes to a better understanding of AML biology and helps identify potential therapeutic targets.

Read More
1 2 3 4

Your compare list

Compare
REMOVE ALL
COMPARE
0